Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.96
-1.6%
$4.47
$3.42
$8.14
$278.82M1.941.63 million shs664,250 shs
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$2.38
+7.2%
$2.77
$2.12
$5.80
$236.38M2.021.50 million shs3.39 million shs
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$2.02
+1.0%
$1.95
$0.77
$4.08
$279.33M1.4910,764 shs650,063 shs
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$1.11
+3.7%
$1.05
$0.83
$5.39
$68.76M1.15738,995 shs381,521 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-2.33%+9.80%+18.59%-23.87%-28.00%
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-3.06%-18.53%-11.90%-36.02%-30.63%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
0.00%+13.64%+16.28%-42.03%+23.84%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-10.08%+0.47%+16.94%-17.69%-74.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.4204 of 5 stars
0.02.00.00.02.40.80.6
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
1.3182 of 5 stars
3.52.00.00.01.80.00.0
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.7967 of 5 stars
4.63.00.00.02.25.00.0
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
1.0912 of 5 stars
3.40.00.00.01.80.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$10.67348.18% Upside
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.11
Buy$13.13549.75% Upside
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
2.80
Moderate Buy$9.00710.81% Upside

Current Analyst Ratings Breakdown

Latest PYXS, ACB, AQST, and CMPX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/9/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
4/28/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/22/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/4/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $24.00
4/2/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/2/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/2/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00 ➝ $6.00
4/1/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.87$0.19 per share26.35$8.18 per share0.61
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$57.56M4.11N/AN/A($1.59) per share-1.50
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$850K328.63N/AN/A$1.17 per share1.73
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$16.15M4.26N/AN/A$2.81 per share0.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.0599.2211.27N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$7.87M-$0.52N/AN/AN/A-59.75%N/A-33.96%N/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$42.49M-$0.41N/AN/AN/AN/A-32.37%-30.67%N/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$73.79M-$1.30N/AN/AN/AN/A-36.22%-28.76%5/15/2025 (Estimated)

Latest PYXS, ACB, AQST, and CMPX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.29-$0.35-$0.06-$0.35N/AN/A
5/12/2025Q1 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million
5/8/2025Q1 2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.12-$0.12N/A-$0.12N/AN/A
3/18/2025Q4 2024
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.33-$0.32+$0.01-$0.60N/A$16.15 million
3/5/2025Q4 2024
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.14-$0.19-$0.05-$0.19$13.11 million$11.87 million
2/27/2025Q4 2024
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.10-$0.11-$0.01-$0.11N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
6.37
5.91
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/A
31.84
31.84
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/A
7.33
7.33

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
68.43%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
39.09%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
8.35%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
28.50%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
9.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
16099.32 million84.02 millionOptionable
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
20138.28 million98.38 millionNot Optionable
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
6061.95 million53.64 millionOptionable

Recent News About These Companies

Pyxis Oncology (PYXS) Projected to Post Earnings on Tuesday
Stifel Nicolaus Keeps Their Buy Rating on Pyxis Oncology (PYXS)
RBC Capital Remains a Buy on Pyxis Oncology (PYXS)
Pyxis Oncology reports FY24 EPS ($1.32), consensus ($1.09)
Pyxis Oncology (PYXS) Gets a Hold from William Blair

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.96 -0.08 (-1.59%)
As of 04:00 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$2.38 +0.16 (+7.21%)
As of 04:00 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Compass Therapeutics stock logo

Compass Therapeutics NASDAQ:CMPX

$2.02 +0.02 (+1.00%)
As of 04:00 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Pyxis Oncology stock logo

Pyxis Oncology NASDAQ:PYXS

$1.11 +0.04 (+3.74%)
As of 04:00 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.